Gene–Disease Research Guide
NFKB2 associated diseases research spans inherited immune dysfunction and context-dependent cancer biology. NFKB2 encodes the p100 precursor that is processed to p52 in the non-canonical NF-κB pathway. Germline truncating variants are established causes of an immunodeficiency phenotype that can include impaired B-cell and germinal-center function, while lymphoma studies show that NFKB2 effects depend strongly on oncogenic context. Creative Biolabs can connect gene–disease evidence review, gene perturbation, and immune-function assays such as cytokine response analysis for research-use validation.
Entity Identity
NFKB2 should be studied at more than the mRNA level: p100 processing to p52, localization, pathway activation, and cell-type-specific immune phenotypes can each answer different questions. That distinction is central when translating variant evidence into an assay plan.
Research-use boundary: Disease associations on this page are intended to help plan mechanistic and validation studies. They are not diagnostic or treatment recommendations.
| Field | Current research reference |
|---|---|
| Official symbol / name | NFKB2 — nuclear factor kappa B subunit 2. |
| Human identifiers | NCBI Gene 4791; HGNC 7795; protein commonly described as p100/p52. |
| Core pathway | Non-canonical NF-κB signaling; p100 processing and p52-containing transcription-factor complexes. |
| Disease evidence emphasized here | Germline truncating variants in immunodeficiency/CVID-like disease; germinal-center defects; MYC-linked lymphomagenesis models. |
| Last scientific check | November 3, 2026; variant interpretation should be re-checked against current databases and family evidence. |
Biological Context
The same gene can produce different experimental consequences in B cells, T-cell subsets, or transformed lymphoid cells. A useful study therefore connects pathway state to the cell type and endpoint.
Variant or signaling defects can alter phosphorylation, proteasomal processing, nuclear translocation, and downstream transcription.
Published NFKB2-mutant cohorts show B-cell abnormalities and reduced Tfh/Tfr-related measures, supporting immune-phenotyping studies.
In Eμ-Myc models, loss of Nfkb2 accelerated lymphomagenesis by impairing a MYC-associated apoptotic response—an example of context-dependent pathway behavior.
Evidence Map
NFKB2 has strong genetic evidence in a primary immunodeficiency phenotype, but tumor findings should be interpreted within the specific oncogenic and model context.
| Association / mechanism | Evidence type | What is supported | What still needs validation |
|---|---|---|---|
| Truncating NFKB2 variants in immunodeficiency | Human family genetics plus functional processing studies | Variants affecting the C terminus disrupted p100 processing and p52 nuclear translocation in affected individuals. | Variant-specific penetrance, endocrine/autoimmune features, and immune phenotypes require case-specific interpretation. |
| Tfh/Tfr and germinal-center phenotype | Human patient immune phenotyping | Reduced Tfh/Tfr-related populations and CXCL13 supported a role for NFKB2 in germinal-center quality. | Small rare-disease cohorts limit broad quantitative generalization. |
| MYC–NFKB2 in lymphomagenesis | Mouse genetic model plus human Burkitt lymphoma observations | MYC suppressed Nfkb2; Nfkb2 loss accelerated lymphoma in Eμ-Myc mice by impairing apoptosis. | The direction of NF-κB effects can differ across tumor types and pathway states. |
| Non-canonical pathway function | Established signaling biology | NFKB2/p100 is a central component of non-canonical NF-κB signaling. | mRNA expression alone does not establish p100 processing or p52 transcriptional activity. |
Study Design
For NFKB2, a single endpoint is rarely enough. Pair genotype or perturbation with pathway processing and cell-function readouts.
Question: Does the candidate NFKB2 change affect p100 abundance, processing, or p52 localization?
Useful readouts: Genotype, p100/p52 protein, nuclear/cytoplasmic distribution, and downstream transcription.
Decision: Establishes whether the variant produces a pathway-level molecular defect.
Question: Are B-cell, Tfh/Tfr, or cytokine phenotypes changed in the selected model?
Useful readouts: Cell subset phenotyping, proliferation, CXCL13/cytokines, activation markers.
Decision: Connects molecular pathway state to an interpretable immune phenotype.
Question: Does NFKB2 loss or restoration change apoptosis in a MYC-driven model?
Useful readouts: MYC status, apoptosis/caspase readouts, proliferation, rescue.
Decision: Tests whether the published lymphoma mechanism is reproduced in the project model.
Validation Workflow
A useful sequence is variant/construct review → model generation → p100/p52 pathway readout → immune or tumor phenotype → rescue. Disease-modeling gene editing can support model construction, while T-cell activation and proliferation assays may be relevant for selected immune questions.
| Stage | Recommended approach | Controls / QC | Primary output |
|---|---|---|---|
| 1. Variant / target review | Define variant, domain, expected protein consequence, or perturbation strategy. | Reference transcript; matched WT; sequence confirmation. | Testable molecular hypothesis. |
| 2. Model generation | Introduce variant, knockout, or controlled rescue in an appropriate cell context. | Independent clones/reagents; off-target review; genotype confirmation. | Validated NFKB2 model. |
| 3. Pathway readout | Measure p100/p52, localization, and selected downstream targets. | Positive pathway stimulus where suitable; loading/normalization controls. | Evidence for pathway-processing impact. |
| 4. Immune or tumor phenotype | Use cell-type-specific assays: proliferation, cytokines, apoptosis, or subset phenotype. | Matched baseline, negative controls, dose/time course. | Functional effect linked to pathway state. |
| 5. Rescue / orthogonal validation | Restore WT or test pathway/oncogene dependence. | Expression matching and orthogonal readout. | Stronger evidence for causal interpretation. |
Project Readiness
Provide enough context to distinguish an expression-association study from a causal gene-function study. Missing items can often be addressed during technical review.
| Input | Required / optional | Preferred information | Why it matters |
|---|---|---|---|
| Research objective | Required | Mechanistic question, disease context, and decision to make | Determines whether the project is association, perturbation, or rescue focused. |
| Gene / construct status | Required | Reference sequence, variant, plasmid, guide design, or existing cell line | Defines what can enter the workflow immediately and what must be built. |
| Model | Required | Cell type, organoid/iPSC context, animal model, species, or primary material | Disease relevance and readout interpretation are model dependent. |
| Controls | Required | Wild-type, non-targeting, vehicle, matched rescue, and/or pathway control | Separates gene-specific effects from editing, delivery, or background effects. |
| Existing data | Optional | Expression, sequencing, imaging, phenotype, or prior perturbation data | Can reduce redundant work and guide assay selection. |
| Target readout | Required | Molecular, cellular, pathway, or phenotype endpoint | Lets the study define a stop/go criterion before experiments begin. |
Interpretation Boundaries
Human NFKB2 immunodeficiency cohorts are necessarily small. Functional evidence is valuable, but quantitative phenotype estimates should not be generalized without caution.
p100 and p52 are not interchangeable readouts. RNA expression may miss a processing or localization defect.
NF-κB can support survival in many cancers, yet specific MYC-driven lymphoma models show tumor-suppressive apoptotic effects. Do not generalize one model across malignancies.
This resource is intended for experimental planning, not clinical variant interpretation, diagnosis, or treatment guidance.
Research Support
Use these modules to move from a literature-supported hypothesis to a defined perturbation, model, and measurable endpoint. The final scope should be agreed for the selected model and materials.
You provide: Variant/guide information, model, desired genotype, and pathway endpoint.
Scope to discuss: Knockout, knock-in, or rescue design plus validation requirements.
Outputs to agree: Genotype/QC records, model material, and agreed molecular readouts.
You provide: Cell type, stimulus, NFKB2 status, cytokines/markers of interest, and controls.
Scope to discuss: Whether cytokine profiling and activation/proliferation answer the proposed immune question.
Outputs to agree: Raw/processed assay data, QC, and model-specific interpretation.
You provide: Oncogenic context, NFKB2 perturbation, model, and death-pathway hypothesis.
Scope to discuss: Assay format, time points, and whether rescue or orthogonal viability measures are needed.
Outputs to agree: Apoptosis readouts and comparative analysis.
Selected Reading
NCBI. NFKB2 nuclear factor kappa B subunit 2. Gene ID 4791; updated 2026. https://www.ncbi.nlm.nih.gov/gene/4791.
Chen K, et al. Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency. American Journal of Human Genetics. 2013;93(5):812-824. https://doi.org/10.1016/j.ajhg.2013.09.009.
Fousteri G, et al. NFKB2 regulates human Tfh and Tfr pool formation and germinal center potential. Clinical Immunology. 2020;210:108309. https://doi.org/10.1016/j.clim.2019.108309.
Keller U, et al. Myc suppression of Nfkb2 accelerates lymphomagenesis. BMC Cancer. 2010;10:348. https://doi.org/10.1186/1471-2407-10-348.
FAQ
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
